Qualified attorney is new Domainex CEO

Hayley French is a qualified attorney with a background in microbiology and significant experience in the life sciences sector. She possesses a proven track record of fostering growth and innovation, having held leadership positions in multiple pharmaceutical and biotechnology organisations. Her areas of expertise include strategic development, business operations, and commercialisation.

Prior to her appointment at Domainex, she occupied several senior leadership roles, including CEO of Apitope International NV before its acquisition by Worg Pharmaceuticals.

She has also held legal positions related to pharmaceutical and biotechnology transactions at Novartis and Bird & Bird in London, in addition to serving as the Head of Legal Affairs at CAMR in the UK. Hayley started her career at UCL Ventures.

“I am honoured to join Domainex and lead this talented team,” she said.

“Domainex is renowned for its innovative approach to drug discovery and its unwavering commitment to delivering high-quality results. I am eager to collaborate with the Domainex team to build upon this strong foundation and drive further success.”

The appointment is effective immediately and she will be based at Domainex's headquarters in Cambridge. Eddy Littler, who has been serving as CEO, will revert to his position as non-executive Chairman.

Littler said: “We are excited to welcome Hayley to Domainex. Her profound understanding of the biotechnology landscape, strategic vision, and exemplary leadership skills render her the ideal individual to steer Domainex through its next stage of growth. We are confident that under her stewardship, Domainex will continue to deliver exceptional value to its clients and partners.”